文献速递肿瘤 PET/CT

4DST PET/CT细胞增殖显像预测食管癌预后的疗效:与FDG PET/CT的对比研究

Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-12

本前瞻性研究纳入46例病理证实的食管鳞状细胞癌患者,治疗前分别行4DST和FDG PET/CT,测量SUVmax、MTV、TLG和TLP。经Cox比例风险模型调整临床变量后,仅4DST参数(SUVmax和TLP)对无进展生存期(PFS)有统计学显著预测价值;FDG MTV、4DST SUVmax和TLP对总生存期(OS)有统计学显著预测价值。4DST SUVmax对PFS和OS的调整风险比最高。

要点

  • 4DST SUVmax和TLP是PFS的独立预测因素,FDG参数均无统计学显著性。
  • 4DST SUVmax对PFS和OS的调整风险比分别为4.88和4.19,为所有PET参数中最高。
  • 4DST PET/CT在预测食管癌预后方面可能优于FDG PET/CT。

核心结论

  • 原发肿瘤4DST摄取较高可能导致更短的OS和PFS。
  • 4DST PET/CT有助于预测预后,可能优于FDG PET/CT。

研究设计与样本

  • 前瞻性研究,纳入46例病理证实的食管鳞状细胞癌患者(68.2 ± 10.0岁),治疗前接受4DST和FDG PET/CT检查。
  • 测量FDG和4DST PET的SUVmax、MTV、TLG和TLP,终点为PFS和OS,采用Cox比例风险模型调整年龄、组织学类型、临床分期和手术治疗等临床背景。

主要发现

  • 中位随访18.8个月(四分位距10.1-29.0),26例疾病进展,19例癌症相关死亡。
  • 调整临床变量后,仅4DST参数(SUVmax p=0.001,TLP p=0.022)对PFS预测有统计学显著性。
  • FDG MTV(p=0.031)、4DST SUVmax(p=0.022)和TLP(p=0.023)对OS预测有统计学显著性。
  • 4DST SUVmax对PFS的调整风险比为4.88(95%CI:1.83-12.97),对OS的调整风险比为4.19(95%CI:1.23-14.20),为所有PET参数中最高。

临床怎么用

  • 治疗前4DST PET/CT可用于食管癌预后分层,SUVmax和TLP较高提示预后不良。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 4'-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal cancer. METHODS: In this prospective study, we analyzed 46 patients (68.2 ± 10.0 years old) with pathologically proven esophageal squamous cell cancer who underwent pretreatment 4DST and FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion proliferation (TLP) were measured for FDG and 4DST PET. The study endpoints were progression-free survival (PFS) and overall survival (OS). Patients' clinical backgrounds, including age, histological type, clinical stage, and surgical treatment, were adjusted using the Cox proportional-hazards model. RESULTS: In the follow-up period (median 18.8 (interquartile range: 10.1-29.0) months), 26 and 19 patients showed disease progression and cancer-related death, respectively. After adjusting for clinical variables, only the 4DST parameters (SUVmax (p = 0.001) and TLP (p = 0.022)) were statistically significant for predicting PFS. FDG MTV (p = 0.031), 4DST SUVmax (p = 0.022), and TLP (p = 0.023) were statistically significant for predicting OS. Of the PET parameters, 4DST SUVmax yielded the highest adjusted hazard ratio for both PFS (4.88, 95% confidence intervals (CI): 1.83-12.97) and OS (4.19, 95% CI: 1.23-14.20). CONCLUSION: Higher accumulation of 4DST in the primary tumor may lead to shorter OS and PFS. 4DST PET/CT is useful for predicting prognosis and may outperform FDG PET/CT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hotta M, Minamimoto R, Toyohara J, et al. Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021. PMID: 33438100. doi:10.1007/s00259-020-05179-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。